Utah Medical Products Inc

UTMD remains in a Stage 2 advancing regime supported by higher highs and higher lows, but price is encountering resistance at the July highs under overbought conditions. Short-term EMAs have flattened and price is holding just above them, reducing immediate upside edge. We will defer new entries and wait for pullbacks into the rising 9-/21-EMA zone, with the 50-DMA providing structural support.

• ↑Quarterly dividend of $0.31 (+1.6% YoY) yields ~0.57%
• ↑Earnings yield ~25% indicates attractive valuation vs peers
• ↓Growth score is negative, suggesting weak expansion potential